Aprinoia Therapeutics
$5.5M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Aprinoia Therapeutics is currently valued at $295.5M as of October 28, 2024. The company has raised a total of $65.0M in funding.
Capital Efficiency
With a capital efficiency ratio of 4.54x, Aprinoia Therapeutics has achieved a valuation that is 4.54 times the total capital raised. This metric indicates strong capital efficiency and effective deployment of investor funds.
Investment Perspective
Aprinoia Therapeutics's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Aprinoia Therapeutics Worth in 2025?
As of 2025, Aprinoia Therapeutics is valued at $295.5M, based on the company's IPO funding round in October 28, 2024. This valuation positions Aprinoia Therapeutics as one of the leading private companies in the sector.
Aprinoia Therapeutics Valuation History
Aprinoia Therapeutics's funding history demonstrates steady growth and investor confidence.
How Aprinoia Therapeutics Valuation is Determined
Private company valuations like Aprinoia Therapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Aprinoia Therapeutics Valuation FAQs
Is Aprinoia Therapeutics profitable?
Aprinoia Therapeutics has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Aprinoia Therapeutics's valuation compare to competitors?
Aprinoia Therapeutics is valued at $295.5M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Aprinoia Therapeutics IPO?
Aprinoia Therapeutics has not announced plans for an initial public offering. Until an IPO, investors can access Aprinoia Therapeutics shares through secondary market platforms.